No Image Provided

Grey Wolf Therapeutics

VC Funding

Series B Angel-backed

Healthcare & Biotech Published 26 January 2023

Summary

In a significant market movement during January 2023, Grey Wolf Therapeutics was the subject of a vc funding. The transaction achieved a gross valuation of £39,553,052. Leading the round was Oxford Science Enterprises, Canaan, Earlybird Venture Capital, Andera Partners, British Patient Capital, Pfizer Ventures.

This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.

Lead Investor / Acquirer

Oxford Science Enterprises

Lead Investor / Acquirer

Canaan

Lead Investor / Acquirer

Earlybird Venture Capital

Lead Investor / Acquirer

Andera Partners

Lead Investor / Acquirer

British Patient Capital

Lead Investor / Acquirer

Pfizer Ventures

Advising Broker

Undisclosed Firm

Related Deals in Healthcare & Biotech

Series B prioritised

VC Funding

Evaro

£18,000,000

Jan 2026

VC Funding

Kraken Technologies

£25,000,000

Jan 2026

VC Funding

Scan.com

£67,220,000

Sept 2026

VC Funding

Ternary Therapeutics

£3,600,000

Mar 2026

View Company Details

Financials, officers, full deal history

Original Source

This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.

View on Tech.eu Funding Explorer

Funding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Free to all registered users.